Kiniksa Pharmaceuticals International (KNSA) was upgraded by Zacks Research from "strong sell" to "hold".
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Kiniksa Pharmaceuticals, Ltd. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wells Fargo & Company from $50.00 to $53.00. They now have an "overweight" rating on the stock.